Evercore ISI Downgrades Bio-Techne to In Line with $73 Price Target
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Evercore ISI downgraded Bio-Techne (TECH) to In Line from Outperform with a $73 price target after the company agreed to be acquired by Merck KGaA (MKGAY) for $73 per share in cash.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TECH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TECH
Wall Street analysts forecast TECH stock price to fall
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 70.920
Low
60.00
Averages
66.14
High
72.00
Current: 70.920
Low
60.00
Averages
66.14
High
72.00
About TECH
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers. This segment also manufactures and sells fully automated multiomic spatial biology instrumentation and advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bio-Techne Launches New Cell Therapy Proteins
- Product Portfolio Expansion: Bio-Techne has launched new R&D Systems AI-Engineered Designer Proteins aimed at enhancing reproducibility and performance in cell culture and therapy workflows, further solidifying its leadership in the life sciences sector.
- Technological Innovation: The new proteins improve heat stability, activity, and solubility, helping researchers overcome variability and scalability challenges in cell culture, thereby achieving more consistent results at clinical and commercial scales.
- Positive Market Feedback: Early adopters report that the IL-2 Heat Stable Agonist Protein provides significant proliferation advantages for Tumor-Infiltrating Lymphocyte samples, reducing costs for TIL therapies, indicating the practical potential of the new products.
- Strategic Implications: Bio-Techne's AI-Engineered Designer Protein portfolio supports not only stem cell culture and organoid development but also enables reproducible scale-up in cell therapy manufacturing, addressing the market's demand for high-performance signaling molecules.
See More
Bio-Techne Launches New Cell Therapy Proteins
- Portfolio Expansion: Bio-Techne has launched new R&D Systems™ AI-Engineered Designer Proteins aimed at enhancing reproducibility and performance in cell culture and therapy development workflows from discovery to production.
- Technological Innovation: The new proteins, including heat-stable FGF-4, FGF-7, and hyperactive IL-15, maintain activity at elevated temperatures, significantly improving cell expansion efficiency and reducing production costs for cell therapies.
- Positive Market Feedback: Early adopters report that the IL-2 Heat Stable Agonist Protein provides a significant proliferation advantage for tumor-infiltrating lymphocyte samples, indicating the platform's broad potential in cell therapy applications.
- Strategic Importance: This product expansion reinforces Bio-Techne's leadership in developing high-performance signaling molecules, supporting organoid culture, stem cell differentiation, and cell therapy manufacturing to meet clinical and commercial scale demands.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies such as Arcosa, Inc., Bio-Techne Corporation, Iridium Communications Inc., and LCI Industries for potential violations of federal securities laws and fiduciary duties to shareholders, including Arcosa's sale to CRH for $150 per share.
- Shareholder Rights: The firm encourages shareholders to contact them to discuss their rights and options at no cost, indicating a commitment to protecting investor interests and potentially seeking increased consideration or other remedies.
- Potential Impact: The terms of these transactions may limit superior competing offers, negatively affecting the financial interests of shareholders, particularly ordinary shareholders who may miss out on financial benefits available to insiders.
- Legal Service Model: Halper Sadeh LLC operates on a contingency fee basis, meaning shareholders do not incur out-of-pocket legal fees or expenses, thereby lowering the barrier for shareholders seeking legal assistance.
See More
Multiple Companies Under Investigation for Merger Deal Fairness
- LCI Merger Investigation: LCI Industries is set to be acquired by Patrick Industries in an all-stock deal where LCI shareholders will receive 1.2440 shares of Patrick for each LCI share, raising concerns about whether the LCI Board breached its fiduciary duties by failing to ensure fair pricing, potentially impacting shareholder value.
- Iridium Acquisition Scrutiny: Iridium Communications will be acquired by Rocket Lab for $54 per share in a cash and stock transaction, representing an enterprise value of approximately $8 billion, with investigations questioning whether the Iridium Board adequately protected shareholder interests during the deal process, risking fair value for shareholders.
- Bio-Techne Merger Review: Bio-Techne Corporation is to be acquired by Merck KGaA for $73 per share in cash, totaling an enterprise value of around $11.3 billion, with investigations focusing on whether the Bio-Techne Board conducted a fair process, potentially affecting shareholder returns.
- Arcosa Merger Investigation: Arcosa will be acquired by CRH for $150 per share in cash, with an enterprise value of approximately $8.5 billion, raising questions about whether the Arcosa Board fulfilled its fiduciary duties to shareholders, possibly leading to inadequate valuation in the transaction.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating several companies, including Synaptics, Iridium Communications, and Bio-Techne, for potential violations of federal securities laws and breaches of fiduciary duties, which may affect shareholder rights.
- Synaptics Transaction: The deal between Synaptics and onsemi involves exchanging each Synaptics share for 1.350 shares of onsemi common stock, potentially limiting superior competing offers and impacting shareholder options.
- Iridium Transaction: Iridium Communications is selling for $27.00 in cash per share and shares of Rocket Lab common stock calculated via an exchange ratio, prompting shareholders to consider the implications of the transaction terms on their rights.
- Bio-Techne Transaction: Bio-Techne is being sold to Merck KGaA for $73.00 per share in cash, and Halper Sadeh LLC may seek increased compensation and additional disclosures for shareholders regarding the transaction.
See More
Investigation into Bio-Techne's Merck Transaction
- Shareholder Rights Investigation: Ademi LLP is investigating Bio-Techne for potential breaches of fiduciary duty in its $11.3 billion transaction with Merck, where shareholders will receive $73 per share, potentially undermining shareholder confidence in corporate governance.
- Competitive Transaction Limitations: The transaction agreement imposes significant penalties on Bio-Techne for accepting competing bids, which could harm shareholder interests and impact the company's future market competitiveness.
- Insider Benefits: Bio-Techne insiders stand to gain substantial benefits from the deal, raising questions about whether the board is fulfilling its fiduciary duties to all shareholders, which may lead to shareholder dissatisfaction with management.
- Legal Action Risks: Ademi LLP specializes in litigation involving buyouts, mergers, and shareholder rights, and if the investigation reveals misconduct by the board, it could trigger legal actions that further affect the company's reputation and shareholder trust.
See More
Bio-Techne Launches New Cell Therapy Proteins
- Product Portfolio Expansion: Bio-Techne has launched new R&D Systems AI-Engineered Designer Proteins aimed at enhancing reproducibility and performance in cell culture and therapy workflows, further solidifying its leadership in the life sciences sector.
- Technological Innovation: The new proteins improve heat stability, activity, and solubility, helping researchers overcome variability and scalability challenges in cell culture, thereby achieving more consistent results at clinical and commercial scales.
- Positive Market Feedback: Early adopters report that the IL-2 Heat Stable Agonist Protein provides significant proliferation advantages for Tumor-Infiltrating Lymphocyte samples, reducing costs for TIL therapies, indicating the practical potential of the new products.
- Strategic Implications: Bio-Techne's AI-Engineered Designer Protein portfolio supports not only stem cell culture and organoid development but also enables reproducible scale-up in cell therapy manufacturing, addressing the market's demand for high-performance signaling molecules.
See More
Bio-Techne Launches New Cell Therapy Proteins
- Portfolio Expansion: Bio-Techne has launched new R&D Systems™ AI-Engineered Designer Proteins aimed at enhancing reproducibility and performance in cell culture and therapy development workflows from discovery to production.
- Technological Innovation: The new proteins, including heat-stable FGF-4, FGF-7, and hyperactive IL-15, maintain activity at elevated temperatures, significantly improving cell expansion efficiency and reducing production costs for cell therapies.
- Positive Market Feedback: Early adopters report that the IL-2 Heat Stable Agonist Protein provides a significant proliferation advantage for tumor-infiltrating lymphocyte samples, indicating the platform's broad potential in cell therapy applications.
- Strategic Importance: This product expansion reinforces Bio-Techne's leadership in developing high-performance signaling molecules, supporting organoid culture, stem cell differentiation, and cell therapy manufacturing to meet clinical and commercial scale demands.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating companies such as Arcosa, Inc., Bio-Techne Corporation, Iridium Communications Inc., and LCI Industries for potential violations of federal securities laws and fiduciary duties to shareholders, including Arcosa's sale to CRH for $150 per share.
- Shareholder Rights: The firm encourages shareholders to contact them to discuss their rights and options at no cost, indicating a commitment to protecting investor interests and potentially seeking increased consideration or other remedies.
- Potential Impact: The terms of these transactions may limit superior competing offers, negatively affecting the financial interests of shareholders, particularly ordinary shareholders who may miss out on financial benefits available to insiders.
- Legal Service Model: Halper Sadeh LLC operates on a contingency fee basis, meaning shareholders do not incur out-of-pocket legal fees or expenses, thereby lowering the barrier for shareholders seeking legal assistance.
See More
Multiple Companies Under Investigation for Merger Deal Fairness
- LCI Merger Investigation: LCI Industries is set to be acquired by Patrick Industries in an all-stock deal where LCI shareholders will receive 1.2440 shares of Patrick for each LCI share, raising concerns about whether the LCI Board breached its fiduciary duties by failing to ensure fair pricing, potentially impacting shareholder value.
- Iridium Acquisition Scrutiny: Iridium Communications will be acquired by Rocket Lab for $54 per share in a cash and stock transaction, representing an enterprise value of approximately $8 billion, with investigations questioning whether the Iridium Board adequately protected shareholder interests during the deal process, risking fair value for shareholders.
- Bio-Techne Merger Review: Bio-Techne Corporation is to be acquired by Merck KGaA for $73 per share in cash, totaling an enterprise value of around $11.3 billion, with investigations focusing on whether the Bio-Techne Board conducted a fair process, potentially affecting shareholder returns.
- Arcosa Merger Investigation: Arcosa will be acquired by CRH for $150 per share in cash, with an enterprise value of approximately $8.5 billion, raising questions about whether the Arcosa Board fulfilled its fiduciary duties to shareholders, possibly leading to inadequate valuation in the transaction.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating several companies, including Synaptics, Iridium Communications, and Bio-Techne, for potential violations of federal securities laws and breaches of fiduciary duties, which may affect shareholder rights.
- Synaptics Transaction: The deal between Synaptics and onsemi involves exchanging each Synaptics share for 1.350 shares of onsemi common stock, potentially limiting superior competing offers and impacting shareholder options.
- Iridium Transaction: Iridium Communications is selling for $27.00 in cash per share and shares of Rocket Lab common stock calculated via an exchange ratio, prompting shareholders to consider the implications of the transaction terms on their rights.
- Bio-Techne Transaction: Bio-Techne is being sold to Merck KGaA for $73.00 per share in cash, and Halper Sadeh LLC may seek increased compensation and additional disclosures for shareholders regarding the transaction.
See More
Investigation into Bio-Techne's Merck Transaction
- Shareholder Rights Investigation: Ademi LLP is investigating Bio-Techne for potential breaches of fiduciary duty in its $11.3 billion transaction with Merck, where shareholders will receive $73 per share, potentially undermining shareholder confidence in corporate governance.
- Competitive Transaction Limitations: The transaction agreement imposes significant penalties on Bio-Techne for accepting competing bids, which could harm shareholder interests and impact the company's future market competitiveness.
- Insider Benefits: Bio-Techne insiders stand to gain substantial benefits from the deal, raising questions about whether the board is fulfilling its fiduciary duties to all shareholders, which may lead to shareholder dissatisfaction with management.
- Legal Action Risks: Ademi LLP specializes in litigation involving buyouts, mergers, and shareholder rights, and if the investigation reveals misconduct by the board, it could trigger legal actions that further affect the company's reputation and shareholder trust.
See More
